Table 2.
ABI Level at Follow-up | |||
---|---|---|---|
Baseline RF Group | N | PAD (≤0.90) vs Normal ABI (1.00 to 1.40) | Borderline PAD (0.91 to 0.99) vs Normal ABI (1.00 to 1.40) |
Model 1* | |||
LR† | 261 | 0.14 (0.05 to 0.44) | 0.28 (0.12 to 0.66) |
0 RFs‡ | 431 | 0.28 (0.13 to 0.59) | 0.39 (0.19 to 0.79) |
1 RF only§ | 451 | 0.33 (0.16 to 0.65) | 0.43 (0.22 to 0.86) |
≥2 RFs§ | 203 | 1.00 | 1.00 |
β Coefficient/P for trend¶ | 0.63/<0.001 | 0.40/0.005 | |
Model 2* | |||
LR† | 259 | 0.16 (0.04 to 0.57) | 0.32 (0.13 to 0.81) |
0 RFs‡ | 430 | 0.31 (0.14 to 0.69) | 0.43 (0.21 to 0.90) |
1 RF only§ | 450 | 0.38 (0.19 to 0.77) | 0.46 (0.23 to 0.94) |
≥2 RFs§ | 201 | 1.00 | 1.00 |
β Coefficient/P for trend¶ | 0.59/<0.001 | 0.34/0.021 |
OR indicates odds ratio; PAD, peripheral arterial disease; RF, risk factor; ABI, ankle-brachial index; LR, low risk; CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Model 1 adjusted for baseline age, sex, race, and education attainment (n=1346). Model 2 adjusted for all variables from model 1 plus current RF status and presence of follow-up MI/major ECG abnormalities (n=1340).
Favorable level of all major CVD RFs (SBP/DBP ≤120/≤80 mm Hg and no antihypertensive medication, serum total cholesterol <200 mg/dL and no lipid-lowering medication, not smoking, BMI <25 kg/m2, no diabetes).
Borderline SBP/DBP or serum total cholesterol, not smoking, BMI 25.0 to 29.9 kg/m2, no diabetes.
High SBP/DBP (≥140/90) or using antihypertensive medication, serum total cholesterol ≥240 mg/dL or using lipid-lowering medication, smoking, BMI ≥30.0 kg/m2, or diabetes.
P value for trend across 4 baseline RF groups based on Wald Chi-Square tests.